HRP20200763T1 - Liječenje dijabetesa tip 1 uz pomoć glp-1 i protutijela protiv il-21 - Google Patents
Liječenje dijabetesa tip 1 uz pomoć glp-1 i protutijela protiv il-21 Download PDFInfo
- Publication number
- HRP20200763T1 HRP20200763T1 HRP20200763TT HRP20200763T HRP20200763T1 HR P20200763 T1 HRP20200763 T1 HR P20200763T1 HR P20200763T T HRP20200763T T HR P20200763TT HR P20200763 T HRP20200763 T HR P20200763T HR P20200763 T1 HRP20200763 T1 HR P20200763T1
- Authority
- HR
- Croatia
- Prior art keywords
- glp
- inhibitor
- function
- agonist
- intended
- Prior art date
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 108010074108 interleukin-21 Proteins 0.000 claims 25
- 239000003112 inhibitor Substances 0.000 claims 21
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 18
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 9
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 2
- 108010019598 Liraglutide Proteins 0.000 claims 2
- 229960002701 liraglutide Drugs 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102100027211 Albumin Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 241000801930 Apterona helix Species 0.000 claims 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461989841P | 2014-05-07 | 2014-05-07 | |
EP14169596 | 2014-05-23 | ||
EP14189732 | 2014-10-21 | ||
PCT/EP2015/059811 WO2015169789A1 (en) | 2014-05-07 | 2015-05-05 | Treatment of diabetes type 1 using glp-1 and anti-il-21 |
EP15720982.6A EP3139948B1 (en) | 2014-05-07 | 2015-05-05 | Treatment of diabetes type 1 using glp-1 and anti-il-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200763T1 true HRP20200763T1 (hr) | 2020-07-24 |
Family
ID=70609983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200763TT HRP20200763T1 (hr) | 2014-05-07 | 2020-05-11 | Liječenje dijabetesa tip 1 uz pomoć glp-1 i protutijela protiv il-21 |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP6824373B2 (da) |
DK (1) | DK3139948T3 (da) |
ES (1) | ES2791879T3 (da) |
HR (1) | HRP20200763T1 (da) |
HU (1) | HUE048860T2 (da) |
PT (1) | PT3139948T (da) |
-
2015
- 2015-05-05 PT PT157209826T patent/PT3139948T/pt unknown
- 2015-05-05 DK DK15720982.6T patent/DK3139948T3/da active
- 2015-05-05 HU HUE15720982A patent/HUE048860T2/hu unknown
- 2015-05-05 ES ES15720982T patent/ES2791879T3/es active Active
-
2019
- 2019-12-19 JP JP2019229235A patent/JP6824373B2/ja active Active
-
2020
- 2020-05-11 HR HRP20200763TT patent/HRP20200763T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PT3139948T (pt) | 2020-05-22 |
HUE048860T2 (hu) | 2020-09-28 |
ES2791879T3 (es) | 2020-11-06 |
JP2020073501A (ja) | 2020-05-14 |
DK3139948T3 (da) | 2020-05-25 |
JP6824373B2 (ja) | 2021-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20202024T1 (hr) | Cd3-vežuća domena | |
HRP20201353T1 (hr) | Agonisti glukagonskog receptora | |
HRP20170905T1 (hr) | Antikancerogeni fuzijski protein | |
HRP20170890T1 (hr) | Suagonisti glukagonskog/glp-1 receptora | |
JP2017532313A5 (da) | ||
AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
JP2018537415A5 (da) | ||
PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
JP2017529067A5 (da) | ||
IL299282A (en) | Enhanced variable complexes of immunoglobulins | |
JP2015509091A5 (da) | ||
PE20240215A1 (es) | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo | |
JP2016536322A5 (da) | ||
JP2016529229A5 (da) | ||
NZ764889A (en) | Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist | |
AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
PE20220938A1 (es) | Compuestos agonistas de gipr | |
JP2019510739A5 (da) | ||
PE20190743A1 (es) | Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib | |
WO2013181087A3 (en) | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy | |
HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
HRP20231118T1 (hr) | Sintetizirani polipeptidi koji vežu transferinske receptore | |
AR107290A1 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
CL2007001835A1 (es) | Metodos para la preparacion de peptidos insulinotropicos, particularmente el peptido similar a glucagon 1 (glp-1) y los homologos del mismo, utilizando procesos en fase solida y en solucion; fragmento peptidico util en la preparacion del peptido insu | |
WO2016057529A3 (en) | Biphasic single-chain insulin analogues |